Table 4.
Univariate analysis for progression-free survival.
| Characteristic | N (Mean PFS *) | 95% CI | p |
|---|---|---|---|
| Sex | 0.794 | ||
| Male | 49 (96) | 81–111 | |
| Female | 39 (85) | 73–98 | |
| Age (years) | 0.102 | ||
| <30 | 28 (68) | 52–83 | |
| ≥30 | 60 (99) | 85–114 | |
| Histological subtype | 0.286 | ||
| NS | 55 (80) | 68–93 | |
| MC | 16 (119) | 105–134 | |
| LR | 8 (49) | 28–70 | |
| NOS | 9 (93) | 66–120 | |
| Ann Arbor stage | 0.016 | ||
| I/II | 38 (89) | 82–97 | |
| III | 10 (73) | 35–111 | |
| IV | 40 (76) | 61–91 | |
| B symptoms at diagnosis | 0.394 | ||
| Present | 53 (91) | 75–107 | |
| Absent | 35 (91) | 72–104 | |
| Bulky disease at diagnosis | 0.055 | ||
| Present | 12 (47) | 27–66 | |
| Absent | 76 (99) | 85–112 | |
| EBV-LMP1 | 0.856 | ||
| Positive | 36 (91) | 71–111 | |
| Negative | 52 (86) | 74–97 | |
| IPS | 0.214 | ||
| 0–2 | 47 (88) | 77–99 | |
| 3–7 | 41 (89) | 72–107 | |
| GHSG | 0.086 | ||
| Limited/Intermediate stages | 23 (75) | 66–83 | |
| Advanced stages | 65 (90) | 75–104 |
* PFS in months. NS, Nodular sclerosis; MC, Mixed cellularity; LR, Lymphocyte-rich; NOS, Not otherwise specified; EBV-LMP1, Epstein–Barr Virus Latent Membrane Protein 1; IPS, International Prognostic Score; GSHG, German Hodgkin Study Group, Cologne, Germany. Boldface font indicates statistical significance (p < 0.05).